520 related articles for article (PubMed ID: 37043676)
21. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD
Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322
[TBL] [Abstract][Full Text] [Related]
22. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
[TBL] [Abstract][Full Text] [Related]
24. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
25. P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV.
Moreira FL; Melli PPDS; Marques MP; Rocha A; Nardotto GHB; Duarte G; Lanchote VL
J Clin Pharmacol; 2023 Feb; 63(2):219-227. PubMed ID: 36087110
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.
Yamazaki T; Desai A; Goldwater R; Han D; Lasseter KC; Howieson C; Akhtar S; Kowalski D; Lademacher C; Rammelsberg D; Townsend R
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):66-75. PubMed ID: 27273004
[TBL] [Abstract][Full Text] [Related]
27. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.
Katsube T; Miyazaki S; Narukawa Y; Hernandez-Illas M; Wajima T
Eur J Clin Pharmacol; 2018 Jul; 74(7):931-938. PubMed ID: 29627897
[TBL] [Abstract][Full Text] [Related]
28. The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.
Tsakalozou E; Adane ED; Kuo KL; Daily A; Moscow JA; Leggas M
Drug Metab Dispos; 2013 Jul; 41(7):1404-13. PubMed ID: 23620484
[TBL] [Abstract][Full Text] [Related]
29. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
[TBL] [Abstract][Full Text] [Related]
30. OATP1B3 Expression and Function is Modulated by Coexpression with OCT1, OATP1B1, and NTCP.
Zhang Y; Ruggiero M; Hagenbuch B
Drug Metab Dispos; 2020 Aug; 48(8):622-630. PubMed ID: 32482756
[TBL] [Abstract][Full Text] [Related]
31. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
Watari R; Sawada H; Hashimoto H; Kasai Y; Oka R; Shimizu R; Matsuzaki T
J Pharm Sci; 2024 Mar; 113(3):798-805. PubMed ID: 37742997
[TBL] [Abstract][Full Text] [Related]
32. The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
Tong Z; Yerramilli U; Surapaneni S; Kumar G
Cancer Chemother Pharmacol; 2014 Apr; 73(4):869-74. PubMed ID: 24627218
[TBL] [Abstract][Full Text] [Related]
33. Novel Explanted Human Liver Model to Assess Hepatic Extraction, Biliary Excretion and Transporter Function.
Stevens LJ; Dubbeld J; Doppenberg JB; van Hoek B; Menke AL; Donkers JM; Alsharaa A; de Vries A; Vaes WHJ; Knibbe CAJ; van de Steeg E; Alwayn IPJ
Clin Pharmacol Ther; 2023 Jul; 114(1):137-147. PubMed ID: 37042227
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
[TBL] [Abstract][Full Text] [Related]
35. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
Shoaf SE; Bricmont P; Repella Gordon J
Clin Transl Sci; 2021 Jul; 14(4):1535-1542. PubMed ID: 33742787
[TBL] [Abstract][Full Text] [Related]
36. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
[TBL] [Abstract][Full Text] [Related]
37. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
38. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
39. Transporter-mediated drug-drug interactions.
Müller F; Fromm MF
Pharmacogenomics; 2011 Jul; 12(7):1017-37. PubMed ID: 21787191
[TBL] [Abstract][Full Text] [Related]
40. Effect of Chronic Hepatitis C on the Activity of the Membrane Transporters P-gp and OATP1B1/BCRP on Patients With Different Stages of Hepatic Fibrosis.
Pippa LF; Vieira CP; Caris JA; Rocha A; Marques MP; Garcia CP; Rezende REF; Lanchote VL
Clin Pharmacol Ther; 2023 Jul; 114(1):173-181. PubMed ID: 37070971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
